NasdaqCM - Nasdaq Real Time Price USD

Tiziana Life Sciences Ltd (TLSA)

Compare

0.8400

+0.1040

+(14.13%)

At close: January 10 at 4:00:01 PM EST

0.8099

-0.03

(-3.58%)

After hours: January 10 at 7:58:49 PM EST

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists discontinuation

GlobeNewswire 2 days ago

TLSA
+14.13%
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a review article titled “Immune mechanisms and shared immune targets in neurodegenerative diseases” was published in Nature Reviews Neurology, highlighting the therapeutic potential o

GlobeNewswire 4 days ago

TLSA
+14.13%
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a significant milestone in its clinical development program for Alzheimer’s disease. The Company has successfully dosed the first patient with moderate Alzheimer's disease using intranasal

GlobeNewswire 26 days ago

TLSA
+14.13%
3 US Penny Stocks With Market Caps Under $200M To Consider

As the Dow, S&P 500, and Nasdaq reach record highs fueled by a surge in technology stocks, investor optimism is palpable. In such a buoyant market climate, penny stocks—often overlooked yet still significant—present intriguing opportunities for those seeking growth potential in smaller or newer companies. Though the term may seem outdated, these stocks can offer substantial returns when backed by solid financials and strategic positioning.

Simply Wall St. last month

TLSA
+14.13%
SQNS

QSI
Tiziana Life Sciences expands Phase 2 trial for non-active SPMS

Tiziana Life Sciences (TLSA) announced the expansion of its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis, SPMS. The trial sites include esteemed institutions across the Northeast of the United States. “We are honored to collaborate with these prestigious institutions as we further expand our clinical trial,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “This milestone demonstrates our dedication to advancing innovative treatmen

TipRanks last month

TLSA
+14.13%
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the expansion of its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS). The trial sites include esteemed institutions ac

GlobeNewswire last month

TLSA
+14.13%
Tiziana Life Sciences Secures ALS Trial Funding

Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences has secured funding from the ALS Association to conduct a 20-patient clinical trial for its innovative intranasal foralumab, a potential therapy aimed at treating ALS. This trial will explore the drug’s safety and early-stage efficacy, with hopes of slowing disease progression in ALS patients. The company’s unique approach aligns with the ALS Association’s mission to find new treatments for this devastating disease. For f

TipRanks last month

TLSA
+14.13%
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its grant application to the ALS Association has been approved for funding. The grant is awarded as part of the Hoffman ALS Clinical Trial Awards Program and is titled “Modulation of

GlobeNewswire last month

TLSA
+14.13%
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry lead

GlobeNewswire 2 months ago

TLSA
+14.13%
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 millionNEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has entered into a securities purchase agreement for

GlobeNewswire 2 months ago

TLSA
+14.13%
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE: NVO) un

GlobeNewswire 2 months ago

TLSA
+14.13%
Discover October 2024's Promising US Penny Stocks

As the U.S. markets experience mixed results with the S&P 500 and Dow Jones snapping their six-week winning streaks, investors are keenly observing economic data and earnings reports for further insights. In this context, penny stocks—often representing smaller or newer companies—remain a compelling area of interest due to their potential for growth and affordability. Despite being considered a niche investment category, these stocks can offer significant opportunities when they possess...

Simply Wall St. 2 months ago

TLSA
+14.13%
BMTX

BMTX-WT
Tiziana Life Sciences Plans Share Sale with Jefferies

Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences Ltd. has announced an agreement to sell its common shares through Jefferies LLC on the open market, with a minimum price set at $1.00 per share. This move is part of a strategic effort to raise capital, leveraging its registration statement with the SEC. Investors may find this an intriguing development as the company seeks to enhance its financial flexibility. For further insights into TLSA stock, check out TipRanks’ Sto

TipRanks 2 months ago

TLSA
+14.13%
Tiziana Life Sciences Advances with Promising Drug Trials

Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences has reported promising progress in its lead programs targeting neurodegenerative and autoimmune diseases, particularly with its drug Foralumab. Encouraging interim results show potential for this drug to offer more effective and less harmful treatments for conditions like multiple sclerosis, with a Phase 2 study underway and FDA Fast Track designation granted. These developments highlight Tiziana’s commitment to innovativ

TipRanks 2 months ago

TLSA
+14.13%
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the National Institutes of Health (NIH), National Institute on Aging have awarded a $4 Million grant to Dr. Howard Weiner as principal investigator at Brigham and Women’s Hospital to be t

GlobeNewswire 3 months ago

TLSA
+14.13%
Tiziana Life Sciences Appoints New Chief Executive Officer

Ivor Elrifi CEO Tiziana Life Sciences Appoints Ivor Elrifi as Chief Executive Officer NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are de

GlobeNewswire 4 months ago

TLSA
+14.13%
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq list

GlobeNewswire 4 months ago

TLSA
+14.13%
Tiziana Life Sciences Granted FDA Fast Track Designation

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its intranasal formulation of foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of

GlobeNewswire 5 months ago

TLSA
+14.13%
Tiziana Receives $3.4 Million in Non-Dilutive Funding

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, “Tiziana is pleased to receive $3.4

GlobeNewswire 6 months ago

TLSA
+14.13%
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer’s disease. Expanded access IND’s provide a pathway for patients to gain access to inv

GlobeNewswire 6 months ago

TLSA
+14.13%

Performance Overview

Return	TLSA	S&P 500
YTD	+12.00%	-1.35%
1-Year	+42.37%	+22.51%
3-Year	-15.15%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tiziana Life Sciences Ltd (TLSA)

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

3 US Penny Stocks With Market Caps Under $200M To Consider

Tiziana Life Sciences expands Phase 2 trial for non-active SPMS

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

Tiziana Life Sciences Secures ALS Trial Funding

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Discover October 2024's Promising US Penny Stocks

Tiziana Life Sciences Plans Share Sale with Jefferies

Tiziana Life Sciences Advances with Promising Drug Trials

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

Tiziana Life Sciences Appoints New Chief Executive Officer

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences Granted FDA Fast Track Designation

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab

Performance Overview